Understanding and Treating Glioblastoma

For newly diagnosed patients, the standard has remained largely unchanged for the past decade and concept-driven approaches like anti-angiogenic therapies or use of molecularly targeted drugs in all-comers populations have failed. Tumor-treating fields appear as a new option. Most current immunother...

Full description

Saved in:
Bibliographic Details
Published inNeurologic clinics Vol. 36; no. 3; p. 485
Main Authors Wick, Wolfgang, Platten, Michael
Format Journal Article
LanguageEnglish
Published United States 01.08.2018
Subjects
Biomarker
Treatment resistance
Precision medicine
MGMT
Immunotherapy
Glioblastoma
Radiomics
Repositioning of drugs
Online AccessGet more information

Cover

More Information
Summary:For newly diagnosed patients, the standard has remained largely unchanged for the past decade and concept-driven approaches like anti-angiogenic therapies or use of molecularly targeted drugs in all-comers populations have failed. Tumor-treating fields appear as a new option. Most current immunotherapy or molecularly targeted, precision medicine trials are also focusing on this newly diagnosed patient population. At progression, no standard exists and most treatments offer little beyond supportive care. Past trials lacked target precision and all-comers approaches have produced false negative results. Molecular precision approaches at progression need workup of recent rather than archival tissue.
ISSN:1557-9875
DOI:10.1016/j.ncl.2018.04.006